01 — At a Glance
The Eyewear Startup That IPO’d Into the Stratosphere
Lenskart is India’s largest organised retailer of prescription eyewear—a market leader with 4–6% of the ₹79,000 crore domestic market. The company went public in November 2025, raised ₹7,278 crore, and immediately became a market darling. Six weeks later, it posted Q3 FY26 numbers that made believers believe even harder. Revenue jumped 37% YoY to ₹2,308 crore. EBITDA (before Ind-AS 116) surged 90% to ₹462 crore. PAT exploded 7,141% YoY to ₹133 crore (off a tiny Q3 FY25 base). The stock is up 24.7% in three months. Market cap? ₹90,311 crore. P/E ratio? 238x. For context, that’s the kind of multiple you see on companies that just invented smartphones, not eyewear retailers. But the story is compelling—eye tests up 54% YoY, 49% of them first-timers, and management claims it’s in a “compounding phase.” Whether that’s genius-level capital allocation or just very expensive eyewear ambition is what we’re here to figure out.
IPO Play Recap: Lenskart raised ₹2,150 crore fresh issue at ₹720/share. IPO priced at Nov 10, 2025. Current trading at ₹520 (vs IPO ₹720). Down 27.8% from listing but still up massively from pre-IPO valuations. Welcome to the world of post-IPO volatility, where your gains are someone else’s buying opportunity and vice versa.
02 — Introduction
From “Fixing Glasses” to “Fixing Your Eyesight Narrative”
Lenskart began in 2008 as a D2C (direct-to-consumer) online eyewear startup. Peyush Bansal and Amit Chaudhary saw a gap: Indians buying expensive spectacles from shady optics shops where the markup was 300–400%. They said, “Let’s blow that up.” And they did—by bundling optometry, manufacturing, and retail under one roof.
Over 16 years, Lenskart became India’s #1 organised eyewear player. They own and operate multiple brands: Lenskart (mass market), Owndays (acquired premium), John Jacobs (style), Vincent Chase (mid-range), Hustlr (budget). They run 2,067 stores in India and 656 internationally. They manufacture frames and lenses in-house at four plants (Gurgaon, Bhiwadi, Singapore, UAE). They have 6.77 million active Gold members and a loyalty retention rate that makes Starbucks jealous (98% repeat rate within 2 years).
But here’s where the story shifts: Lenskart just stopped being a “retail startup” and started being an “AI-powered demand-creation machine.” Management now talks about eye tests (6.3 million globally in Q3) as the real business—not eyewear sales. The pitch is TAM expansion, not market share grabbing. And suddenly, a company selling ₹3,000 spectacles is trading at ₹90,000 crore market cap. Is this visionary capital deployment or a mirage? Let’s see.
Founder Holding Alert: Promoters hold only 17.57% post-IPO. That’s weak founder conviction relative to IPO proceeds. The largest individual shareholder is SVF II Lightbulb (Cayman) Limited at 13.14%, indicating Softbank’s still-dominant voting power. This matters when analysing capital allocation decisions.
03 — Business Model: More Than Just 20/20 Vision
They Don’t Sell Eyewear. They Sell Confidence.
Lenskart’s traditional model: person walks in → optometrist does eye test → technician fits frame + cuts lens → customer walks out with ₹2,500–₹15,000 glasses. Revenue generated. Profit margins: gross margin 68%, EBITDA margin 15% (FY25 full year). The math works.
But the new model (as of FY25–FY26): person doesn’t walk in—the eye test comes to them. Remote optometry. Home tests. AI-assisted diagnosis. Then they buy. The aim is to expand the TAM from 25 million units sold annually to a potential 500 million units (India’s refractive error population). Management’s 10-year vision? ₹4 lakh crore eyewear market (vs ₹79,000 crore today). That’s a 5x expansion narrative.
Revenue streams: (a) Prescription eyewear (80%, core), (b) Sunglasses (Meller acquisition), (c) Contact lenses, (d) Accessories & services. New bets: smart glasses (Phonic, launched Dec 2024), data centre cooling fluids (just kidding—that’s Castrol). But seriously, Lenskart positioning itself as “graduating from eyewear to intelligence”—capturing prescriptions, face geometry, purchase patterns, and using AI to personalise at scale.
India Stores2,067+169 net in Q3
Intl Stores656+26 net in Q3
Gold Members6.77MActive repeaters
Eye Tests Q36.3M+54% YoY
The Real Model: Lenskart is not trying to sell you a pair of spectacles. It’s trying to own your eye data, predict your eyesight trajectory, and then sell you the right product at the right time. That’s why eye tests matter more than units sold. TAM expansion is the game, not SAM capture.
💬 Have you bought from Lenskart? Did you feel like a customer, or data being harvested for the “intelligence company” future? Drop your take!
04 — Financials Overview
Q3 FY26: The Numbers That Broke the Internet
Result type: Quarterly Results (Consolidated) | Q3 FY26 EPS: ₹1.70 (annualised) | Full-year FY26 will differ | 9M FY26 PAT: ₹326 Cr (vs ₹137 Cr last year)
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 2,308 | 1,669 | 2,096 | +37.4% | +10.1% |
| EBITDA (Pre-IAS 116) | 462 | 243 | 413 | +90.1% | +11.9% |
| EBITDA Margin % | 20.0% | 14.6% | 19.7% | +540 bps | +30 bps |
| PAT | 133 | 2 | 103 | +7,141% | +29.1% |
| EPS (₹) | 0.76 | 0.02 | 1.24 | +7,141% | -38.7% |
The Annualisation Drama: Q3 is typically weak for eyewear (post-New Year resolution shopping dies down). But Lenskart delivered +37% YoY revenue and 20% EBITDA margins anyway. Annualised EPS (Q3×4) would be ₹3.04, implying a P/E of 171x (vs reported 238x using full-year FY25 EPS). Still absurd, but slightly less absurd. The real story: 9-month PAT is ₹326 crore vs ₹137 crore last year. That’s a 2.4x jump on a 9-month basis—clean operating leverage in action.
05 — Valuation: Fair Value Range
How Much Should You Actually Pay for Eyewear?
Join 10,000+ investors who read this every week.
